- Home
- About
- Resource Library
- Mental Health Disorders
- Agitation
- Anxiety Disorders
- Bipolar Disorder
- Cognition
- Depression
- Eating Disorders
- Personality Disorders
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Women’s Health
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Early Episode Psychosis
- Health Care Policy & Legislation
- Neuroscience
- Payer & Financing Models
- Quality Standards & Performance Measures
- Stigma
- Suicide Awareness
- Wellness
- Collections
- Featured
- Monthly Spotlight
- Psychopharmacology
- Learning Tracks
- Community Insights
- Community Podcast
- Disease Management & Support Tools
- Frameworks In Health & Quality Resources
- Mental Health System Guidebooks
- Patient & Caregiver Resource Center
- PsychU Roleplay
- Psychiatric Scales
- PsychUSim
- Events
Virtual Event – The Evolving Psychopharmacology Of Major Depressive Disorder
Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Virtual Event – The Evolving Psychopharmacology Of Major Depressive Disorder
In this presentation, the objectives are to:
- Provide a brief overview of depression prevalence and current standard treatments
- Review the monoamine hypothesis of depression
- Discuss alternative hypotheses of depression
- Highlight potential new therapeutic intervention targets
Featuring
Philip G. Janicak, MD
Adjunct Professor and Consultant to the Therapeutic Neuromodulation Program in the Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine and a Distinguished Life Fellow in the American Psychiatric Association
MoreDr. Janicak is an Adjunct Professor and Consultant to the Therapeutic Neuromodulation Program in the Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine and a Distinguished Life Fellow in the American Psychiatric Association. He completed his medical training and psychiatric residency at Loyola University of Chicago in 1976. In 1978, he became a research psychiatrist at the Illinois State Psychiatric Institute. He was a Professor of Psychiatry and Pharmacology, the Medical Director of the Psychiatric Clinical Research Center, and the Associate Program Director for the NIH General Clinical Research Center at the University of Illinois Medical Center from 1994-2004. He then became a Professor of Psychiatry at Rush University and was the Director of the Rush Psychiatric Clinical Research and Transcranial Magnetic Stimulation Centers from 2004-2014. He developed and directed the TMS Center at Linden Oaks Medical Group from 2014-2017.
Dr. Janicak’s primary research interests are in the assessment and treatment of mood and psychotic disorders. In this context, he has conducted over 60 clinical trials. He has been a NIH grant awardee as both a principal and co-investigator. He has authored, co-authored or edited over 500 publications in the psychiatric literature and is first author of the Principles and Practice of Psychopharmacotherapy.
Dr. Janicak was the editor of the Psychopharm Review from 2004-2014 and presently serves on the Editorial Board of Current Psychiatry. He has also been a reviewer for several journals, including: The American Journal of Psychiatry, Biological Psychiatry, JAMA Psychiatry, Journal of the American Medical Association, Journal of ECT, Journal of Clinical Psychiatry, Journal of Clinical Psychopharmacology, Psychiatric Annals, Psychiatry Research and Schizophrenia Research.
Dr. Janicak was first listed in the Best Doctors of America since 1996 and Who’s Who in America in 2001. Dr. Janicak was named Psychiatrist of the Year by NAMI Illinois for 2003. In 2009, he received the John M. Davis Researcher of the Year Award from NAMI of Greater Chicago. In 2017, he was a recipient of the Who’s Who Albert Nelson Marquis Lifetime Achievement Award. In 2018, he was the recipient of the Illinois Psychiatric Society Educator of the Year Award. He has participated as a principal lecturer in over 500 courses, seminars, symposia and related professional presentations.Rachel Self, PhD, MS (OPDC)
Clinical & Scientific Director
Related Events
-
Virtual Event – Monoamine Theory In Depression: Implications For Disease & Treatment
June 3 12:00 pm to 1:00 pm -
Virtual Event – Monoamine Theory In Depression: Implications For Disease & Treatment
June 3 7:00 pm to 8:00 pm -
Virtual Event – Proposed Role Of Modulating Norepinephrine In Psychiatry Illnesses
June 7 7:00 pm to 8:00 pm
Registration
Related Resources
-
Re-Imagining The Dopamine Hypothesis Of Schizophrenia: How Can We Find A Balance?
On-Demand Webinar May 24, 2022The dopamine hypothesis of schizophrenia has been foundational in elucidating the benefit of dopamine-blocking actions of antipsychotic medications over the past 60 years. Although blocking the D2 receptors may lead…
-
16% Of Community Mental Health Centers Use Measurement-Based Care, Despite Knowledge Of Value
Article May 23, 2022As of October 2021, 83% of community mental health center (CMHC) executives said that “their organization is familiar with the value of using measurement-based care (MBC)”, however just 16% were…
-
New Florida Law Exempts Antipsychotics From Medicaid Step Therapy
Article May 23, 2022On April 6, 2022, Florida enacted a bill to exempt Medicaid beneficiaries diagnosed with schizophrenia from step-therapy authorizations for antipsychotic medications. Under the new law, the beneficiary can be exempted…
Stay Connected:
- Resource Library